Determination of debrisoquine and 4-hydroxydebrisoquine in urine by high-performance liquid chromatography with fluorescence detection after solid-phase extraction.
A simple, selective and sensitive method has been developed to determine debrisoquine and 4-hydroxydebrisoquine in human urine. Separation of the analytes was obtained using a mobile phase of 0.1 M sodium dihydrogen phosphate-acetonitrile (87:13, v/v) and a muBondapak C18 column. The column effluent was monitored with fluorescence detection at 210 nm (ex) and 290 nm (em). Rapid sample preparation was achieved by solid-phase extraction columns (Bond Elut CBA, 3 ml capacity) which provided excellent recovery values for both compounds. The cost per sample using this approach could be minimized by column regeneration and re-use. The within-day and the day-to-day reproducibilities were less than 7% for both components. The method was shown to be suitable for the study of the debrisoquine-sparteine type genetic polymorphism in man.
Bozkurt
A
A
Department of Pharmacology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Basci
N E
NE
Isimer
A
A
Kayaalp
S O
SO
D000097:Acetonitriles / Q000737:chemistry; D002851:Chromatography, High Pressure Liquid; D003647:Debrisoquin / Q000031:analogs & derivatives* / Q000652:urine*; D006801:Humans; D010710:Phosphates / Q000737:chemistry; D011110:Polymorphism, Genetic; D012680:Sensitivity and Specificity; D013050:Spectrometry, Fluorescence
D000097:Acetonitriles; D010710:Phosphates; C012359:4-hydroxydebrisoquin; C018279:sodium phosphate; D003647:Debrisoquin; C032159:acetonitrile